Journal
CANCER TREATMENT REVIEWS
Volume 95, Issue -, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2021.102175
Keywords
Gastric cancer; Microsatellite Instability; Immunocheckpoint inhibitors; Clinical trials; Molecular subtypes
Categories
Funding
- Italian Association for Cancer Research (AIRC)
- AIRC [IG 23624]
- FPRC 5X1000
Ask authors/readers for more resources
Gastric cancer is a significant contributor to the global burden of cancer, with microsatellite instable (MSI) tumors showing promising survival outcomes and potential for immune checkpoint inhibitors treatment. However, conflicting results have been reported in chemotherapy settings.
Gastric cancer (GC) represents an important contributor to the global burden of cancer, being one of the most common and deadly malignancies worldwide. According to TCGA and ACRG classifications, the microsatellite instable (MSI) group represents a significant subset of GCs and is currently in the limelight of many researches due to its favorable survival outcome in resectable stages compared to microsatellite stable tumors. MSI GCs hypermutated phenotype triggers immunosurveillance, making this molecular subgroup a promising candidate for immune checkpoint inhibitors treatment. Conversely, conflicting outcomes have been reported in chemotherapy settings. Due to the clinical relevance of these observations, in this review we report and discuss the molecular, pathological, prognostic, and predictive features of MSI gastric tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available